BD (Becton, Dickinson and Company) announced on August 4, 2025, plans to invest over $35 million and add approximately 50 new jobs to expand prefilled flush syringe manufacturing at its Columbus, Nebraska, facility. This investment aims to increase the resiliency of the U.S. healthcare system.
The investments will support new BD® PosiFlush™ Prefilled Flush Syringe production lines, product innovation, and operational efficiencies. This expansion will enable BD to produce hundreds of millions of additional units annually to meet the growing demand from U.S. hospitals and health systems.
BD PosiFlush™ Syringes are essential for catheter care and maintenance, helping prevent complications and safely delivering medications. This announcement builds on over $80 million invested by BD over the past three years to expand PosiFlush™ capacity, increasing U.S. production by more than 750 million units, including a 10% increase this year alone.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.